# Entos Pharmaceuticals

> The Entos Fusogenix™ PLV™ technology is ideal for the delivery of next generation nucleic acid-based therapies.
Unlike conventional lipid-based delivery systems, our Fusogenix PLV technology is well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique PLV formulations to effectively deliver a wide range of nucleic acid therapies, including gene therapy, mRNA, miRNA, RNAi, and CRISPR.

## Pages

- [Home](https://entospharma.com/)
- [Technology](https://entospharma.com/technology)
- [Pipeline & Partners](https://entospharma.com/pipeline-%26-partners)
- [Team](https://entospharma.com/team)
- [News & Media](https://entospharma.com/news-%26-media)
- [Careers & Culture](https://entospharma.com/careers-%26-culture-1)
- [Contact Entos Pharmaceuticals for Inquiries & Information](https://entospharma.com/contact)
- [Nick Nelson](https://entospharma.com/nick-nelson)

## Contact

Location: Global Headquarters:  Unit 4550, 10230 Jasper Avenue, Edmonton, AB, T5J 4P6, Canada

Email: info@entospharma.com

Email: info@entospharma.com

Email: media@entospharma.com

Email: careers@entospharma.com

Phone: 800-727-0884

## Social Media

- [Facebook](https://www.facebook.com/entospharma)
- [Instagram](https://www.instagram.com/entospharma)
- [Linkedin](https://www.linkedin.com/company/18084780)